[Form 4] Twist Bioscience Corporation Insider Trading Activity

Rhea-AI Filing Summary

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corporation (TWST), reported a sale on 09/08/2025. The Form 4 shows a non-discretionary sell-to-cover transaction of 269 shares of common stock at $25.76 per share to satisfy tax withholding obligations arising from Restricted Stock Unit vesting. Following the transaction, the reporting person beneficially owns 103,037 shares directly. The filing was signed by an attorney-in-fact on behalf of the reporting person on 09/10/2025.

Positive

• Timely and clear disclosure of the transaction in accordance with Section 16 reporting requirements
• Transaction was a sell-to-cover for tax withholding, indicating it was not a discretionary sale reflecting insider sentiment

Negative

• Sale reduced direct holdings (269 shares), though the amount is small relative to total ownership
• Limited detail about the RSU grant date or total vested RSUs is not provided in this Form 4

Insights

Financial Analyst

TL;DR: Routine sell-to-cover for RSU taxes; immaterial to company fundamentals given small size relative to total holdings.

The 269-share sale at $25.76 reflects a mandatory tax-withholding sale tied to RSU vesting rather than a voluntary disposition signaling sentiment change. The post-transaction direct ownership of 103,037 shares remains substantial for an executive but the disposed amount represents approximately 0.26% of those holdings, indicating no material change to insider exposure or control. For investors, this is a compliance-driven filing with negligible impact on capitalization or share supply.

Corporate Governance Expert

TL;DR: Filing demonstrates standard insider reporting and internal equity plan mechanics; timing and size are unremarkable.

This Form 4 clearly discloses that the sale was executed under the issuer's sell-to-cover practice to satisfy tax liabilities from RSU vesting. The disclosure meets Section 16 reporting requirements and was timely signed by an attorney-in-fact. From a governance perspective, routine tax-related dispositions maintain transparency and do not indicate unusual insider activity or governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		S		269(1)	D	$25.76	103,037	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dennis Cho report on the Form 4 for TWST?

The Form 4 reports a sale of 269 shares on 09/08/2025 at $25.76 per share to cover tax withholding from RSU vesting; post-transaction ownership is 103,037 shares.

Was the sale by Dennis Cho discretionary or mandatory?

The filing states the sale was a sell-to-cover mandated by the issuer's equity plan to satisfy tax withholding and was not a discretionary trade.

How material is the transaction relative to Dennis Cho's holdings?

The sale of 269 shares is immaterial relative to the reported 103,037 shares beneficially owned after the transaction, representing a small fraction of total holdings.

When was the Form 4 signed and by whom?

The Form 4 was signed on behalf of Dennis Cho by Kendra Fox, as Attorney-in-Fact, on 09/10/2025.

Does the Form 4 indicate any derivative transactions or additional sales?

No. The filing shows only the non-derivative sale of common stock tied to tax withholding; no derivative transactions are reported.